UOC
MLTX icon

UBS O'Connor’s MoonLake Immunotherapeutics MLTX Stock Holding History

UBS O'Connor’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,740
Closed -$1.12M – 412
2024
Q4 		$1.12M Buy
20,740
+4,740
+30% +$242K 0.03% 218
2024
Q3 		$807K Buy
+16,000
New +$750K 0.02% 299

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

UBS O'Connor's MLTX Position: Q1 2025 in Review

UBS O'Connor sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2025, closing a stake of 20,740 shares — an estimated $1.12M sold.

UBS O'Connor first reported a position in MLTX in Q3 2024 and held it in 2 quarters. The position peaked at $1.12M in Q4 2024. 136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

  • UBS O'Connor reported no remaining MoonLake Immunotherapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 20,740 MoonLake Immunotherapeutics shares in Q1 2025, an estimated $1.12M.
  • UBS O'Connor first reported a position in MoonLake Immunotherapeutics in Q3 2024 and held it in 2 quarters.
  • UBS O'Connor's MoonLake Immunotherapeutics position peaked at $1.12M in Q4 2024.
  • 136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.